Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | The future of tau therapies for movement disorders

Adam Boxer • 9 Sep 2020
MDS 2020
Movement Disorders

Adam Boxer, MD, PhD, UCSF Weill Institute for Neurosciences, San Francisco, CA, discusses the future of discovering a successful tau therapy for movement disorders such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Prof. Boxer shows confidence in anti-tau therapies from genetic data and believes each trial failure progresses the search for a successful candidate. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Adam Boxer

2:00
The 4 Repeat Tauopathy Neuroimaging Initiative
Adam Boxer • 9 Sep 2020
8:08
Promising advanced tau therapies for movement disorders
Adam Boxer • 9 Sep 2020
0:56
Introducing tauopathies and movement disorders
Adam Boxer • 9 Sep 2020

Related Videos

5:26
Pridopidine shows benefit for patients with early HD not on antidopaminergic therapies
Michael Hayden • 16 Apr 2024
2:51
Overlap in etiology between different FND subtypes
Mark Hallett • 15 Apr 2024
1:58
Ambroxol & other targeted therapies in Parkinson's
K Ray Chaudhuri • 21 Mar 2024
3:00
The use of precision medicine in Parkinson’s disease
K Ray Chaudhuri • 21 Mar 2024
The content of VJNeurology is intended for healthcare professionals